Biophytis Delays Publication of 2024 Annual Financial Statements

Biophytis SA, a biotechnology company focused on treatments for age-related diseases, announced a delay in publishing its 2024 annual financial statements. The company, listed on Euronext Growth Paris, initially planned to release the accounts on an earlier date but now intends to publish them by July 7.

Biophytis is based in Paris, with subsidiaries in Massachusetts, USA, and Brazil. The firm's lead drug candidate, BIO101, targets muscular and metabolic disorders. Despite the delay in financial reporting, the company aims to proceed with its development plans.

The announcement highlights the financial challenges Biophytis faces as it navigates through regulatory and developmental complexities in the biotechnology sector.